Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Texas Biotech deal

TXB completed its previously announced acquisition of ImmunoPharmaceutics Inc., a developer

Read the full 111 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE